Table 4 Associated mutations noted on NGS along with response data
Cancer type | HER2/neu status | Associated mutations | Best response | Agent | PFS (weeks) | OS (weeks) |
|---|---|---|---|---|---|---|
Cholangioca | Mutation (V777L) | FGFR3, TP53 | SD | Trastuzumab | 19 | 29 |
Cholangioca | Amplification | BAP1, CDKN2A, KDM6A, PBRM1, SETD2 | PD | Trastuzumab | 14 | 25 |
Cholangioca | Mutation (S310F) | KRAS, MYC, TP53, EZH2, MSH6 | PD | Trastuzumab | 7 | 7 |
Cholangioca | Amplification | Â | PD | Trastuzumab | 6 | 8 |
Cholangioca | Amplification | Â | PD | Trastuzumab | 10 | 12 |
Gallbladder cancer | Amplification | PIK3CA, CDKN2A/B, TP53, ZNF703 | MR | Lapatinib | 15 | 19 |
Gallbladder cancer | Amplification | TP53 | PR | Trastuzumab | >92 | >92 |
Gallbladder cancer | Amplification | NRAS, PIK3CA, RB1,PTEN, TP53 | PR | Trastuzumab | >40 | >62 |
Gallbladder cancer | Amplification | Â | PR | Trastuzumab | 168 | 178 |
Gallbladder cancer | Amplification | Â | PR | Trastuzumab | 38 | 113 |
Gallbladder cancer | Amplification | FGFR3-TACC3 fusion, TP53, CCNE1, MCL1, MYC | SD | Trastuzumab + pertuzumab | +8 | +8 |